Targeting XKR7: A Potential Drug or Biomarker for Various Diseases

Target Name: XKR7

NCBI ID: G343702

XKR7

Targeting XKR7: A Potential Drug or Biomarker for Various Diseases

XKR7 (dJ310O13.4), a protein found in human placenta, has been identified as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. Its unique structure and subcellular localization make it an attractive target for small molecules, antibodies, or other therapeutic agents.

XKR7, named after its discovery by researchers, has a molecular weight of approximately 13,000 Daltons and a pre-folded structure of 13.4% of the theoretical value, indicating a high stability and rigidity. XKR7 is a transmembrane protein that functions as a receptor, playing a crucial role in various physiological processes, including cell signaling, angiogenesis, and immune regulation.

XKR7's unique subcellular localization in the placenta makes it an attractive target for drugs that can modulate its expression or activity. The placenta is a vital organ that plays a critical role in the development and maintenance of fetal tissues, and its dysfunction has been implicated in numerous diseases, including preterm birth, low birth weight, and various forms of cancer. Therefore, targeting XKR7 could potentially lead to new therapeutic approaches for these diseases.

One of the main advantages of XKR7 as a drug target is its accessibility through the blood-brain barrier (BBB). The BBB is a specialized barrier that separates the brain from the blood, and its strict regulation of what enters or leaves the brain makes it difficult for many drugs to reach the central nervous system (CNS). However, XKR7 is known to be expressed in the CNS, which could make it an attractive target for drugs that can bypass the BBB.

In addition to its potential drug target properties, XKR7 also has been shown to play a crucial role in the development and progression of various diseases. For example, high levels of XKR7 have been observed in brain tumors, including glioblastoma multiforme (GBM), one of the most common and aggressive types of cancer. Additionally, XKR7 has been implicated in the development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, as well as autoimmune diseases, such as multiple sclerosis and rheumatoid arthritis.

The identification of XKR7 as a potential drug target has led to a growing interest in the development of small molecules and antibodies that can modulate its expression or activity. Many researchers have investigated the effects of various small molecules, such as drugs used to treat cancer, on XKR7's expression and activity. Some of these small molecules have shown promise in preclinical studies, with some even being tested in clinical trials.

Another approach to targeting XKR7 is the use of antibodies. Antibodies are naturally occurring proteins that can recognize and bind to specific molecules in the body, including XKR7. By using antibodies to target XKR7, researchers can potentially modulate its expression or activity and improve its function as a drug target.

In conclusion, XKR7 is an attractive drug target or biomarker due to its unique structure and subcellular localization, as well as its accessibility through the blood-brain barrier. Its potential as a drug target for various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases makes it an important area of research for the development of new therapeutic approaches. With further investigation, the role of XKR7 as a drug target or biomarker may continue to grow, leading to new treatments and cures for a variety of diseases.

Protein Name: XK Related 7

The "XKR7 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about XKR7 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets